Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.


OTCPK:HALB - Post by User

<< Previous
Bullboard Posts
Next >>
Post by badgirl007on Feb 24, 2021 2:21pm
97 Views
Post# 32648871

HALB and ANTI AGING! Do not forget this!

HALB and ANTI AGING! Do not forget this!A process, which is the basis of a corona treatment from HALB, is at the same time provided as a revoulutionary possibility of anti-aging.

https://www.otcmarkets.com/stock/BIEI/news/Anti-Aging-Patent-Application-Filed-Exclusive-Commercial-Rights-to-Premier-Biomedical-Inc?id=183100

Anti-Aging Patent Application Filed; Exclusive Commercial Rights to Premier Biomedical, Inc.

JACKSON CENTER, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) -

Premier Biomedical, Inc. (OTC:BIEI) announced today the filing of a patent application, “Method For Slowing The Aging Process”, by Mitchel S. Felder, MD, the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical.  

Through its exclusive patent license agreement, Premier Biomedical will have exclusive rights to practice the invention.

The patent application involves the removal of certain antigens associated with the aging process through an extracorporeal (outside the body) treatment of a patient’s blood. 

By targeting these antigens with a complexing agent, causing them to bind together, they can be easily removed before returning the blood to the patient.  This process can target several known aging antigens, such as mTOR (mammalian target of rapamycin), interleukin-6, TGF-beta, oxygen free radicals, Progerin, lipofuscin, etc.

Dr. Felder stated, “This approach, which is considerably different from other currently popular approaches to slow the aging process, attempts to slow aging by utilizing the extra-corporeal removal of the specific antigens involved in the pathophysiologic process of aging in the precise picogram/ml quantities and combinations which would truly slow the aging process.”

William A. Hartman, President & CEO of Premier Biomedical, stated, “This patent application significantly advances Premier Biomedical's intellectual property by being an extension of our existing issued patents on the treatment of disease via extra-corporeal means. What is SO EXCITING about this anti-aging patent application is:

  1. Anti-aging has been sought by mankind since the beginning of recorded time.
  2. The core of this technology is the selective removal of blood-borne antigens associated with aging and is consistent with our core technology. This is explained in the YouTube Video "A Scientific Roadmap to Cure Cancer" (https://youtu.be/BGdZqHH6oew)
  3. We have already proven in the laboratory that we can remove selected blood-borne antigens from a mixture using our technology.
  4. Development of this technology toward commercial status could begin immediately-- first in the laboratory; then in small animals; and lastly in humans.
  5. Commercial application could be accelerated since nothing will be added to human blood, rather only the offending antigens causing aging would be removed.

This could be a BLOCK BUSTER, and the development could be greatly accelerated with the availability of adequate funding.”
Dr. Felder, a prolific inventor, is Board Certified and a Diplomate of the Academy of Neurology, and holds multiple granted U.S. & foreign patents.



 

<< Previous
Bullboard Posts
Next >>